Safe Withdrawal From Antidepressants and Dependence-Forming Medicines: A NICE NG215 Guide

Many people in care homes, community services and hospitals take medicines that can be hard to stop: antidepressants, benzodiazepines, Z-drugs for sleep, opioid painkillers and gabapentinoids. When a person wants to come off one of them, or when a review concludes that it is no longer helping, how the dose is reduced matters a great deal. NICE guideline NG215 covers safe prescribing and withdrawal management for adults taking these medicines. This guide summarises what it says and what care and health staff can do to support safe, person-centred withdrawal. It is general information, not clinical advice, and decisions about stopping a medicine belong to the prescriber and the person.

Which medicines NG215 covers

NICE says the guideline addresses opioids, benzodiazepines, gabapentinoids, Z-drugs and antidepressants in primary and secondary care. It excludes gabapentinoids prescribed for epilepsy, opioids for acute pain, cancer pain or end-of-life care, and the management of illicit drug dependence. It covers supporting people who take a dependence-forming medicine or an antidepressant, starting a medicine (including information and support), management planning, prescribing strategies, working with other healthcare professionals, reviewing a medicine and making shared decisions about withdrawal.

A collaborative relationship from the start

The guideline asks professionals to foster collaborative, trusting and supportive relationships with people considering or taking these medicines. In practice, that means giving clear information about benefits, risks and the possibility of withdrawal symptoms before the medicine is started, agreeing a plan for review, and making decisions together. For care staff, it means listening to residents and clients who say they want to reduce a medicine, or who report that it is not working, and passing this on rather than dismissing it.

How reduction should work: slowly and stepwise

NICE advises a slow, stepwise rate of reduction that is proportionate to the existing dose, so that the decreases become smaller as the dose gets lower. This applies to opioids, benzodiazepines, Z-drugs and antidepressants. For gabapentinoids, NICE suggests reducing by a fixed amount at each step, unless clinical risk means rapid withdrawal is needed. The guideline also says not to stop a medicine abruptly unless there are exceptional medical circumstances, such as serious side effects. The practical message for staff is that withdrawal plans should be written down by the prescriber, followed exactly and not compressed because a person seems to be coping.

Withdrawal can be difficult and can take months

NICE recognises that withdrawal can be difficult and may take several months or more, and that withdrawal symptoms vary widely in type and severity. Symptoms people report include anxiety, low mood, sleep disturbance, irritability, dizziness, sweating, nausea, flu-like feelings, tingling and, with some medicines, pain. These can resemble the original condition returning, so it is important not to assume that every symptom is relapse. If a person is withdrawing and their mood, sleep or behaviour changes, tell the prescriber, who can decide whether to slow the reduction, hold the dose or review the plan.

NICE also says that withdrawal symptoms should not be treated with another medicine that is associated with dependence. That is a useful reminder for staff who may be asked to give a sedative or sleeping tablet for a symptom that is actually withdrawal.

Benzodiazepines and Z-drugs

For benzodiazepines, NICE says to consider switching to a benzodiazepine with a longer half-life as part of reduction, and to consider group cognitive behavioural therapy (CBT) to support withdrawal. These decisions are made by specialists and prescribers. Staff who support people on long-term benzodiazepines or Z-drugs can help by recording sleep, mood and falls, since sedating medicines raise the risk of falls and daytime drowsiness. Our guide to insomnia and Z-drugs explains why sleeping tablets are meant to be short-term, and our guide to generalised anxiety and panic disorder sets out what NICE advises instead of long-term benzodiazepines.

Reviews: how often and how

NICE says that reviews should be offered according to the type of medicine, the dose and the person's individual risk factors, and that they can take place by phone, video or in person. Reviews are a chance to ask whether the medicine is still needed, whether side effects are outweighing benefits and whether a reduction is now sensible. Staff can help by making sure review dates are recorded, that the person attends or is supported to join, and that the care plan reflects the outcome. For older adults taking many medicines, see our guide to polypharmacy and deprescribing.

What care staff can do

• Take requests to reduce seriously. Pass them on to the prescriber and record the conversation.
• Follow the written plan. Give exactly the dose agreed for each step, and never skip, double or stop doses without advice.
• Monitor and record. Note mood, sleep, anxiety, pain, appetite, falls and behaviour changes, because these help the clinician distinguish withdrawal from relapse.
• Offer non-drug support. Sleep routines, activity, relaxation, social contact and psychological therapies all help.
• Escalate quickly. Seek urgent advice for severe agitation, confusion, seizures, hallucinations or suicidal thoughts.
• Respect capacity and consent. People with capacity can decide to reduce or continue; where capacity is lacking, follow best interests processes.

Frequently asked questions

Can a person just stop an antidepressant if they feel better?

NICE advises against stopping abruptly except in exceptional medical circumstances. They should speak to the prescriber about a slow reduction plan.

Are antidepressants addictive?

NG215 groups them with dependence-forming medicines because many people experience withdrawal symptoms when stopping, which is why a slow reduction is advised. The guideline treats this as a withdrawal and safety issue.

Where can staff learn more?

Medicines safety, deprescribing and recognising deterioration are all relevant. Browse the Learnsignal CPD hub for healthcare compliance courses.

Source: NICE guideline NG215, Safe prescribing and withdrawal management of dependence-forming medicines and antidepressants. Always check the current guideline. This article is general information, not clinical advice.